Beneficial effects of amiodarone in heart failure: Interaction with β-adrenoceptors rather than G proteins

European Journal of Pharmacology

Volumn 369, Issue 3, 1999, Pages 391-394

  Schnabel, Petra ^a   Mies, Florian ^a   Maack, Christoph ^a   Rosenkranz, Stephan ^a   Zolk, Oliver ^a   Böhm, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Adenylyl cyclase; Amiodarone; G protein; Heart failure; adrenoceptor

Indexed keywords

ADENYLATE CYCLASE; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYANOPINDOLOL I 125; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANYLYLIMIDODIPHOSPHATE; ISOPRENALINE; RADIOLIGAND;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE MUSCLE; HUMAN; HUMAN TISSUE; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0032891648     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00101-6     Document Type: Article

References (16)

1. +-ATPase in guinea-pig heart preparations. Gen. Pharmacol. 29:1997;639-643.
2. Candinas R., Frielingsdorf J., Ha H.R., Carrel T., Turina M., Follath F. Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. Eur. J. Clin. Pharmacol. 53:1998;331-336.
3. Cleland J.G.F., Bristow M.R., Erdmann E., Remme W.J., Swedberg K., Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur. Heart J. 17:1996;1629-1639.
4. Drvota V., Brönnegard M., Häggblad J., Barkhem T., Sylven C. Downregulation of thyroid hormone receptor subtype mRNA levels by amiodarone during catecholamine stress in vitro. Biochem. Biophys. Res. Commun. 211:1995;991-996.
5. Drvota V., Carlsson B., Häggblad J., Sylven C. Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype β1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect. J. Cardiovasc. Pharmacol. 26:1995;222-226.
6. Freedman M.D., Somberg J.C. Pharmacology and pharmacokinetics of amiodarone. J. Clin. Pharmacol. 31:1991;1061-1069.
7. Gonska B.D. Amiodarone. Internist. 24:1993;981-985.
8. Hagelüken A., Nürnberg B., Harhammer R., Grünbaum L., Schunack W., Seifert R. The class III antiarrhythmic drug amiodarone dirctly activates pertussis toxin-sensitive G proteins. Mol. Pharmacol. 47:1995;234-240.
9. Kowey P.R., Marinchak R.A., Rials S.J., Bharucha D. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Am. J. Cardiol. 80(8A):1997;16G-23G.
10. Massie B.M., Fisher S.G., Deedwania P.C., Singh B.N., Fletcher R.D., Singh S.N. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation. 93:1996;2128-2134. for the CHF-STAT investigators.
11. Matsumori A., Ono K., Nishio R., Nose Y., Sasayama S. Amiodarone inhibits production of tumor necrosis factor-α by human mononuclear cells. Circulation. 96:1997;1386-1389.
12. 1) transgenic rats. Eur. J. Pharmacol. 330:1997;35-46.
13. Singh B.N. Controlling cardiac arrhythmias: an overview with a historical perspective. Am. J. Cardiol. 80(8A):1997;4G-15G.
14. Singh S.N., Fletcher R.D., Fisher S.G., Singh B.N., Lewis H.D., Deedwania P.C., Massie B.M., Colling C., Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: survival trial of arrhythmic therapy in congestive heart failure. N. Engl. J. Med. 333:1995;77-82.
15. Yin Y., Vassy R., Nicolas P., Perret G.Y., Laurent S. Antagonism between T3 and amiodarone on the contractility and the density of beta-adrenoceptors of chicken cardiac myocytes. Eur. J. Pharmacol. 261:1994;97-104.
16. Zolk O., Flesch M., Schnabel P., Teisman A.C., Pinto Y.M., van Gilst W.H., Paul M., Böhm M. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats. Br. J. Pharmacol. 123:1998;405-412.